Wolverine Trading
CRVS icon

Wolverine Trading’s Corvus Pharmaceuticals CRVS Stock Holding History

Wolverine Trading’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,500
Closed -$40.8K – 5703
2025
Q2 		$40.8K Sell
10,500
-2,800
-21% -$10.2K ﹤0.01% 4388
2025
Q1 		$45K Buy
+13,300
New +$62.6K ﹤0.01% 4447
2024
Q4 		– Sell
-14,100
Closed -$72.6K – 5351
2024
Q3 		$72.6K Buy
+14,100
New +$50.6K ﹤0.01% 4441
2023
Q3 		– Sell
-15,400
Closed -$34.3K – 4584
2023
Q2 		$34.3K Buy
+15,400
New +$32K ﹤0.01% 4030
2022
Q2 		– Sell
-14,200
Closed -$22K – 4672
2022
Q1 		$22K Buy
+14,200
New +$26K ﹤0.01% 5235
2021
Q4 		– Sell
-31,000
Closed -$196K – 6032
2021
Q3 		$196K Buy
+31,000
New +$91.8K ﹤0.01% 5369

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return